Champion Industries Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CHMP research report →
Price Chart
About the company
Champion Industries, Inc. , together with its subsidiaries, engages in the production, printing, and sale of printed materials in the United States. The company offers printed materials, including brochures, pamphlets, reports, tags, continuous, and other forms.
- CEO
- Adam Reynolds
- IPO
- 1993
- Employees
- 316
- HQ
- Huntington, WV, US
Get TickerSpark's AI analysis on CHMP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $1.13K
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 9.77
- Div Yield
- 0.00%
- Gross Margin
- 23.20%
- Op Margin
- -1.07%
- Net Margin
- -2.07%
- ROE
- -49.45%
- ROIC
- -5.17%
Latest fiscal year · YoY change
- Revenue
- $62.23M+1.5%
- Gross Profit
- $14.44M-4.9%
- Op Income
- $-668,670
- Net Income
- $-1,286,577-8.0%
- EPS
- $-23.03-4.7%
- OCF Growth
- -99.9%
- FCF Growth
- +101.1%
- 52W High
- $0.02
- 52W Low
- $0.00
- 50D MA
- $0.02
- 200D MA
- $0.02
- Beta
- 0.77
- RSI (14)
- 100
- Avg Volume
- 34
No earnings-call transcripts are available for CHMP yet.
- Free Float
- 94.4%
- Shares Outstanding
- 56.50K
- Float Shares
- 53.35K
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 28, 14 | Evans Justin Todd | other | 0 |
| Dec 2, 13 | REYNOLDS MARSHALL T | buy | 435,839 |
| Nov 20, 13 | REYNOLDS MARSHALL T | buy | 1,888,635 |
| Oct 29, 13 | REYNOLDS MARSHALL T | buy | 726,398 |
| Oct 28, 13 | REYNOLDS MARSHALL T | buy | 242,133 |
| Oct 22, 13 | REYNOLDS MARSHALL T | buy | 1,549,649 |
| May 8, 13 | Pruett Robert L. | other | 0 |
| Apr 8, 13 | Boates Timothy D | other | 0 |
| May 21, 12 | Straub Jeffrey J. | other | 0 |
| Mar 1, 12 | CLINE PHILIP E | buy | 188 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CHMP coverage
Recent articles, reports, and earnings notes.
No research on CHMP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CHMP report →Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
gurufocus.com · Sep 18
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
gurufocus.com · Aug 6
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
gurufocus.com · Jun 29
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
gurufocus.com · Jun 26
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
gurufocus.com · Jun 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.